Update on quality of life in patients with acromegaly

Crespo, Iris; Valassi, Elena; Webb, Susan M.

doi:10.1007/s11102-016-0761-y

Cited by 42 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, QoL in this patient sample was consistent with previous reports [24]. However, as is to be expected in patients with acromegaly, the AcroQoL questionnaire identified several health-related issues, mostly pain and discomfort (affecting 68.5% of the sample), findings that are in line with previous reports showing that joint and musculoskeletalrelated pain are present in up to 90% of patients [24].…”

Section: Quality Of Life Outcomessupporting

confidence: 92%

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

et al. 2020

View full text Add to dashboard Cite

Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and wellreceived among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. Methods Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded. Results Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8-189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%. Conclusion Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.

show abstract

Section: Quality Of Life Outcomessupporting

confidence: 92%

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Successful therapy is usually followed by improvement in the AcroQoL score, but disease control may not normalize QoL scores completely, as evidenced with generic questionnaires with normative data. When comparing QoL in different pituitary patients with generic questionnaires, acromegalic patients score worse for physical ability and functioning and bodily pain than non-functioning pituitary adenomas (NFPA) or prolactinomas, and the presence of hypopituitarism further impairs their well-being and QoL (33).…”

Section: Acromegalymentioning

confidence: 99%

“…Increased psychopathology (mainly anxiety and depression), maladaptative personality traits or less effective coping strategies have been described in patients with controlled acromegaly, which in turn may affect cognition and QoL (2,33,34,35,36) (Fig. 1).…”

Section: Acromegalymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. Design: Critical review of the pertinent literature and pragmatic discussion of available information. Methods: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. Results: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. Conclusions: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.

show abstract

“…Patients with acromegaly experience low quality of life especially during the active stages of the disease [41]. A recent survey conducted in nine pituitary Centres across Germany, the UK, and the Netherlands highlighted factors that impact the lives of patients with acromegaly.…”

Section: Challenges For Development Of An Oral Formulation Of Somatosmentioning

confidence: 99%

Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly

Fattah

Brayden

2017

Ther. Deliv.

View full text Add to dashboard Cite

A 14 amino acid cystin bridge containing neuropeptide was discovered in 1973 and designated as growth hormone-inhibiting hormone, in other words, somatostatin. Its discovery led to the synthesis of three analogs which were licensed for the treatment of acromegaly: octreotide, lanreotide and pasireotide. Somatostatin analogs are currently approved only as either subcutaneous or intramuscular long-acting injections. We examine the challenges that must be overcome to create oral formulations of somatostatin analogs and examine selected clinical trial data. While octreotide has low intestinal permeability, similar to almost all other peptides, it has an advantage of being more stable against intestinal peptidases. The development of new oral formulation strategies may eventually allow for the successful oral administration of potent somatostatin analogs with high therapeutic indices.

show abstract

Update on quality of life in patients with acromegaly

Cited by 42 publications

References 30 publications

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly

Contact Info

Product

Resources

About